1 / 14

Silymarin As Antifibrotic

Silymarin As Antifibrotic. Amany A.Maqsod Sholkamy Professor of Internal Medicine &Hepatology Faculty of Medicine Cairo University Consultant Liver Transplantation Kasr AlAiny H Supervisor of the Liver ICU French H Cairo University. Silybum Marianum. Actions:.

tiara
Télécharger la présentation

Silymarin As Antifibrotic

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Silymarin As Antifibrotic Amany A.MaqsodSholkamy Professor of Internal Medicine &Hepatology Faculty of Medicine Cairo University Consultant Liver Transplantation Kasr AlAiny H Supervisor of the Liver ICU French H Cairo University

  2. SilybumMarianum

  3. Actions: • Antioxidants, and regulators of intracellular content of glutathione. • Inhibitors of stellate hepatocyte transformation into myofibroblasts. • Cell membrane stabilizers.

  4. Limitations: • Studies suggest that the presence of liver damage, particularly as chronic inflammation, may affect the bioavailability of the different forms of silymarin.

  5. Antifibrotic: • Many experimental studies showed a significant antifibrotic effect of silymarin. • No large scale clinical trials addressing specifically the effect of silymarin compounds on liver fibrosis in human.

  6. Antifibrotic: • The available studies lack dose/substance standardization, tissue assessment(fibrosis scores) and long term follow up.

  7. Antioxidant: • Available data suggest a hepatoprotective effect through many mechanisms mainly as an antioxidant affecting inflammatory pathways and stellate cell activation.

  8. In cirrhosis: • Through the (HALT-C) study, observation of cirrhotic patients (1049 pts) taking silymarin revealed an inverse relation between its use and progression of the disease but no effect on clinical outcome. • That was an observational study. No standard dose or duration of use of the drug

  9. In NAFLD: • Again studies lack tissue assessment of fibrosis progression. • Many studies revealed a beneficial effect on parameters such as GGT, markers of steatosis and fibrosis. • Others were biased by the associated dietary restrictions included in the study design.

  10. In chronic viral diseases: • Studies involving patients with chronic HCV showed conflicting and contradictory results raising the need for further larger scale studies. • One of the drawbacks of many studies is the lack of standard type/dose of silymarin form used.

  11. In the transplant setting: • Two case reports indicated that therapy with intravenous silibinin successfully eradicated the virus after transplantation. • Still, further larger scale studies are needed to consider the drug as a specific antifibrotic treatment.

  12. Consensus: • Oral and IV silymarin and its extracts have a hepatoprotective effect and may have a role as an adjuvant treatment in chronic liver diseases. (1A)

  13. Consensus: • The exact dose of these products to be used in different liver diseases is not yet identified. (2C) • The use of silymarin or its extracts as a primary antifibrotic therapy is still waiting evidence.(2C)

  14. Consensus: • Silymarin and its extract Silybin(silibinin) have minimal side effects even in high doses.(1B) Their use in the transplant setting showed minimal drug-drug interactions with the immunsupressive drugs.(2C)

More Related